Eli Lilly Retatrutide Achieves Phase 3 Obesity Weight Loss **FACT BLOCK:** Lilly's Retatrutide met primary endpoint. Patients lost ~25% body weight. Phase 3 trial results are significant. New efficacy benchmark established. Eli Lilly announced groundbreaking Phase 3 results for Retatrutide, its investigational triple G-agonist. The trial successfully met its primary endpoint, demonstrating an average weight reduction of approximately 25% in participants with obesity. This substantial metric surpasses current therapeutic benchmarks, positioning Retatrutide as a potential in the obesity treatment landscape. The trial's success underscores the drug's potent mechanism of action. This positive Phase 3 outcome paves the way for Eli Lilly to initiate regulatory submissions. Under FDA guidelines, a New Drug Application (NDA) will likely follow, leveraging these robust efficacy data. The EMA will also require a Marketing Authorisation Application (MAA). Such submissions typically involve comprehensive data packages, including clinical safety and efficacy, as outlined in 21 CFR Part 314. Expedited review pathways could be sought given the unmet medical need. Retatrutide's efficacy sets a formidable challenge for competitors like Novo Nordisk's Wegovy and pipeline candidates. This performance could redefine market share in the multi-billion-dollar obesity sector. Eli Lilly is now poised to dominate. Expect an NDA submission to the FDA by late Q4 2026.